Intensity Therapeutics (INTS) Liabilities and Shareholders Equity (2022 - 2026)

Intensity Therapeutics (INTS) has 5 years of Liabilities and Shareholders Equity data on file, last reported at $12.3 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 301.01% year-over-year to $12.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $40.4 million (up 85.98% YoY) and the FY2025 annual result came in at $14.1 million, up 194.81% from the prior year.
• Liabilities and Shareholders Equity fell to $12.3 million in Q1 2026, from $14.1 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $18.2 million in Q2 2023 to a low of $1.8 million in Q4 2022.
• A 5-year average of $9.9 million and a median of $9.6 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity jumped 884.35% — and 2025, when it sank 75.3%.
• Tracing INTS's Liabilities and Shareholders Equity over 5 years: stood at $1.8 million in 2022, then jumped by 884.35% to $17.3 million in 2023, then slumped by 72.34% to $4.8 million in 2024, then soared by 194.81% to $14.1 million in 2025, then slipped by 12.84% to $12.3 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $12.3 million (Q1 2026), $14.1 million (Q4 2025), and $9.6 million (Q3 2025), per Business Quant data.